Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Confluence of Symptoms and Treatments at FDA Patient Meetings

This article was originally published in RPM Report

Executive Summary

The first round of four PDUFA patient-focused meetings concluded with the Sept. 24 meeting on narcolepsy. FDA is beginning to look ahead to the fiscal 2014 meetings – to start with fibromyalgia on December 10. One pattern that is emerging is that three of the first five conditions discussed with patients have overlapping symptoms and treatments.

You may also be interested in...

PRO-ving Ground: FDA Review Teams Commit to Patient-Reported Outcomes

FDA recently announced a significant step in furthering the development of patient-reported outcomes: the planned creation of a web-based compendium of clinical outcomes assessments, including PROs. But an even more significant sign that FDA is committed to developing new patient-reported endpoints came directly from reviewers – including some divisions that have not historically been out front on the issue.

Patient Feedback Pioneers: Chronic Fatigue Advocates Prepare for First PDUFA V Meeting

FDA has selected CFS/ME as the first topic for the PDUFA V patient-centered drug development initiative. The lessons learned from this session will inform future work on patient engagement in drug development both for FDA—and for patient advocates.

Getting a Jump on PDUFA V: Fast Start on REMS, Patient Input – And Longer Reviews

The new Prescription Drug User Fee Act Program doesn’t take effect until October 1, but FDA has been getting moving on some key elements of the program since before the final negotiations began on Capitol Hill. FDA will need to move fast to meet the many policy deadlines set by the agreement negotiated with industry.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts